Top

Published in:

Open Access 01-08-2016 | Original Article

RETRACTED ARTICLE: Long non-coding RNA TUSC7 acts a molecular sponge for miR-10a and suppresses EMT in hepatocellular carcinoma

Authors: Yufeng Wang, Zhikui Liu, Bowen Yao, Changwei Dou, Meng Xu, Yumo Xue, Linglong Ding, Yuli Jia, Hongyong Zhang, Qing Li, Kangsheng Tu, Yang Jiao, Qingguang Liu, Cheng Guo

Published in: Tumor Biology | Issue 8/2016

Abstract

Despite advances in the roles of long non-coding RNA (lncRNA) tumor suppressor candidate 7 (TUSC7) in cancer biology, which has been identified as a tumor suppressor by regulating cell proliferation, apoptosis, migration, invasion, cell cycle, and tumor growth, the function of TUSC7 in hepatocellular carcinoma (HCC) remains unknown. In this study, we observed that the expression of TUSC7 was immensely decreased in HCC. Clinically, the lower expression of TUSC7 predicted poorer survival and may be an independent risk factor for HCC patients. Moreover, TUSC7 inhibited cell metastasis, invasion, and epithelial-to-mesenchymal transformation (EMT) through competitively binding miR-10a. Furthermore, we found that TUSC7 could decrease the expression of Eph tyrosine kinase receptor A4 (EphA4), a downstream target of miR-10a as well as an EMT suppressor, through TUSC7-miR-10a-EphA4 axis. Taken together, we demonstrate that TUSC7 suppresses EMT through the TUSC7-miR-10a-EphA4 axis, which may be a potential target for therapeutic intervention in HCC.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.CrossRef

Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245–55. doi:10.1016/S0140-6736(11)61347-0.CrossRef

El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–27. doi:10.1056/NEJMra1001683.CrossRef

Gurzu S, Turdean S, Kovecsi A, Contac AO, Jung I. Epithelial-mesenchymal, mesenchymal-epithelial, and endothelial-mesenchymal transitions in malignant tumors: an update. World J Clin Cases. 2015;3(5):393–404. doi:10.12998/wjcc.v3.i5.393.CrossRef

Bottoni P, Isgro MA, Scatena R. The epithelial-mesenchymal transition in cancer: a potential critical topic for translational proteomic research. Expert Rev Proteomics. 2016;13(1):115–33. doi:10.1586/14789450.2016.1112742.CrossRef

Zuo J, Wen J, Lei M, Wen M, Li S, Lv X, et al. Hypoxia promotes the invasion and metastasis of laryngeal cancer cells via EMT. Med Oncol. 2016;33(2):15. doi:10.1007/s12032-015-0716-6.CrossRef

Li H, Xu F, Li S, Zhong A, Meng X, Lai M. The tumor microenvironment: an irreplaceable element of tumor budding and epithelial-mesenchymal transition-mediated cancer metastasis. Cell Adhes Migr. 2016. doi:10.1080/19336918.2015.1129481.CrossRef

Matouk IJ, Halle D, Raveh E, Gilon M, Sorin V, Hochberg A. The role of the oncofetal H19 lncRNA in tumor metastasis: orchestrating the EMT-MET decision. Oncotarget. 2015. doi:10.18632/oncotarget.6387.

Jun JH, Joo CK. MicroRNA-124 controls transforming growth factor beta1-induced epithelial-mesenchymal transition in the retinal pigment epithelium by targeting RHOG. Invest Ophthalmol Vis Sci. 2016;57(1):12–22. doi:10.1167/iovs.15-17111.CrossRef

10.

Nagano T, Fraser P. No-nonsense functions for long noncoding RNAs. Cell. 2011;145(2):178–81. doi:10.1016/j.cell.2011.03.014.CrossRef

11.

Zhang J, Fan D, Jian Z, Chen GG, Lai PB. Cancer specific long noncoding RNAs show differential expression patterns and competing endogenous RNA potential in hepatocellular carcinoma. PLoS One. 2015;10(10):e0141042. doi:10.1371/journal.pone.0141042.CrossRef

12.

Chen S, Shao C, Xu M, Ji J, Xie Y, Lei Y, et al. Macrophage infiltration promotes invasiveness of breast cancer cells via activating long non-coding RNA UCA1. Int J Clin Exp Pathol. 2015;8(8):9052–61.

13.

Liang WC, Fu WM, Wong CW, Wang Y, Wang WM, Hu GX, et al. The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer. Oncotarget. 2015;6(26):22513–25.CrossRef

14.

Cheng Z, Guo J, Chen L, Luo N, Yang W, Qu X. A long noncoding RNA AB073614 promotes tumorigenesis and predicts poor prognosis in ovarian cancer. Oncotarget. 2015;6(28):25381–9. doi:10.18632/oncotarget.4541.CrossRef

15.

Sun YW, Chen YF, Li J, Huo YM, Liu DJ, Hua R, et al. A novel long non-coding RNA ENST00000480739 suppresses tumour cell invasion by regulating OS-9 and HIF-1alpha in pancreatic ductal adenocarcinoma. Br J Cancer. 2014;111(11):2131–41. doi:10.1038/bjc.2014.520.CrossRef

16.

Peng Y, Li Z, Li Z. GRP78 secreted by tumor cells stimulates differentiation of bone marrow mesenchymal stem cells to cancer-associated fibroblasts. Biochem Biophys Res Commun. 2013;440(4):558–63. doi:10.1016/j.bbrc.2013.09.108.CrossRef

17.

Meseure D, Drak Alsibai K, Nicolas A, Bieche I, Morillon A. Long noncoding RNAs as new architects in cancer epigenetics, prognostic biomarkers, and potential therapeutic targets. BioMed Res Int. 2015;2015:320214. doi:10.1155/2015/320214.CrossRef

18.

Cabanski CR, White NM, Dang HX, Silva-Fisher JM, Rauck CE, Cicka D, et al. Pan-cancer transcriptome analysis reveals long noncoding RNAs with conserved function. RNA Biol. 2015;12(6):628–42. doi:10.1080/15476286.2015.1038012.CrossRef

19.

Ding YC, Yu W, Ma C, Wang Q, Huang CS, Huang T. Expression of long non-coding RNA LOC285194 and its prognostic significance in human pancreatic ductal adenocarcinoma. Int J Clin Exp Pathol. 2014;7(11):8065–70.

20.

Qi P, Xu MD, Shen XH, Ni SJ, Huang D, Tan C, et al. Reciprocal repression between TUSC7 and miR-23b in gastric cancer. Int J Cancer J Int du Cancer. 2015;137(6):1269–78. doi:10.1002/ijc.29516.CrossRef

21.

Pasic I, Shlien A, Durbin AD, Stavropoulos DJ, Baskin B, Ray PN, et al. Recurrent focal copy-number changes and loss of heterozygosity implicate two noncoding RNAs and one tumor suppressor gene at chromosome 3q13.31 in osteosarcoma. Cancer Res. 2010;70(1):160–71. doi:10.1158/0008-5472.CAN-09-1902.CrossRef

22.

Qi P, Xu MD, Ni SJ, Huang D, Wei P, Tan C, et al. Low expression of LOC285194 is associated with poor prognosis in colorectal cancer. J Transl Med. 2013;11:122. doi:10.1186/1479-5876-11-122.CrossRef

23.

Tong YS, Zhou XL, Wang XW, Wu QQ, Yang TX, Lv J, et al. Association of decreased expression of long non-coding RNA LOC285194 with chemoradiotherapy resistance and poor prognosis in esophageal squamous cell carcinoma. J Transl Med. 2014;12:233. doi:10.1186/s12967-014-0233-y.CrossRef

24.

Ohtsuka M, Ling H, Doki Y, Mori M, Calin GA. MicroRNA processing and human cancer. J Clin Med. 2015;4(8):1651–67. doi:10.3390/jcm4081651.CrossRef

25.

Qi X, Zhang DH, Wu N, Xiao JH, Wang X, Ma W. ceRNA in cancer: possible functions and clinical implications. J Med Genetics. 2015. doi:10.1136/jmedgenet-2015-103334.CrossRef

26.

Tuo YL, Li XM, Luo J. Long noncoding RNA UCA1 modulates breast cancer cell growth and apoptosis through decreasing tumor suppressive miR-143. Eur Rev Med Pharmacol Sci. 2015;19(18):3403–11.

27.

Zhao X, Wang P, Liu J, Zheng J, Liu Y, Chen J, et al. Gas5 exerts tumor-suppressive functions in human glioma cells by targeting miR-222. Mol Ther. 2015;23(12):1899–911. doi:10.1038/mt.2015.170.CrossRef

28.

El-Halawany MS, Ismail HM, Zeeneldin AA, Elfiky A, Tantawy M, Kobaisi MH, et al. Investigating the pretreatment miRNA expression patterns of advanced hepatocellular carcinoma patients in association with response to TACE treatment. BioMed Res Int. 2015;2015:649750. doi:10.1155/2015/649750.CrossRef

29.

Safari A, Seifoleslami M, Yahaghi E, Sedaghati F, Khameneie MK. Upregulation of miR-20a and miR-10a expression levels act as potential biomarkers of aggressive progression and poor prognosis in cervical cancer. Tumour Biol. 2015. doi:10.1007/s13277-015-4064-0.CrossRef

30.

Yu T, Liu L, Li J, Yan M, Lin H, Liu Y, et al. MiRNA-10a is upregulated in NSCLC and may promote cancer by targeting PTEN. Oncotarget. 2015;6(30):30239–50. doi:10.18632/oncotarget.4972.CrossRef

31.

Yan Y, Wang Q, Yan XL, Zhang Y, Li W, Tang F, et al. miR-10a controls glioma migration and invasion through regulating epithelial-mesenchymal transition via EphA8. FEBS Lett. 2015;589(6):756–65. doi:10.1016/j.febslet.2015.02.005.CrossRef

32.

Yan Y, Luo YC, Wan HY, Wang J, Zhang PP, Liu M, et al. MicroRNA-10a is involved in the metastatic process by regulating Eph tyrosine kinase receptor A4-mediated epithelial-mesenchymal transition and adhesion in hepatoma cells. Hepatology. 2013;57(2):667–77. doi:10.1002/hep.26071.CrossRef

33.

Bourgin C, Murai KK, Richter M, Pasquale EB. The EphA4 receptor regulates dendritic spine remodeling by affecting beta1-integrin signaling pathways. J Cell Biol. 2007;178(7):1295–307. doi:10.1083/jcb.200610139.CrossRef

34.

Giaginis C, Tsoukalas N, Bournakis E, Alexandrou P, Kavantzas N, Patsouris E, et al. Ephrin (Eph) receptor A1, A4, A5 and A7 expression in human non-small cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival. BMC Clin Pathol. 2014;14(1):8. doi:10.1186/1472-6890-14-8.CrossRef

35.

Takano H, Nakamura T, Tsuchikawa T, Kushibiki T, Hontani K, Inoko K, et al. Inhibition of Eph receptor A4 by 2,5-dimethylpyrrolyl benzoic acid suppresses human pancreatic cancer growing orthotopically in nude mice. Oncotarget. 2015;6(38):41063–76. doi:10.18632/oncotarget.5729.CrossRef

36.

Lu H, Clauser KR, Tam WL, Frose J, Ye X, Eaton EN, et al. Addendum: A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol. 2015;17(12):1607. doi:10.1038/ncb3281.CrossRef

37.

Ogunwobi OO, Liu C. Therapeutic and prognostic importance of epithelial-mesenchymal transition in liver cancers: insights from experimental models. Crit Rev Oncol Hematol. 2012;83(3):319–28. doi:10.1016/j.critrevonc.2011.11.007.CrossRef

38.

Liu Q, Huang J, Zhou N, Zhang Z, Zhang A, Lu Z, et al. LncRNA loc285194 is a p53-regulated tumor suppressor. Nucleic Acids Res. 2013;41(9):4976–87. doi:10.1093/nar/gkt182.CrossRef

39.

Sun J, Bie B, Zhang S, Yang J, Li Z. Long non-coding RNAs: critical players in hepatocellular carcinoma. Int J Mol Sci. 2014;15(11):20434–48. doi:10.3390/ijms151120434.CrossRef

40.

Yuan SX, Wang J, Yang F, Tao QF, Zhang J, Wang LL, et al. Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1. Hepatology. 2015. doi:10.1002/hep.27893.CrossRef

41.

Chen CL, Tseng YW, Wu JC, Chen GY, Lin KC, Hwang SM, et al. Suppression of hepatocellular carcinoma by baculovirus-mediated expression of long non-coding RNA PTENP1 and microRNA regulation. Biomaterials. 2015;44:71–81. doi:10.1016/j.biomaterials.2014.12.023.CrossRef

42.

Xie B, Lin W, Ye J, Wang X, Zhang B, Xiong S, et al. DDR2 facilitates hepatocellular carcinoma invasion and metastasis via activating ERK signaling and stabilizing SNAIL1. J Exp Clin Cancer Res CR. 2015;34(1):101. doi:10.1186/s13046-015-0218-6.CrossRef

43.

Mazzotta A, Partipilo G, De Summa S, Giotta F, Simone G, Mangia A. Nuclear PARP1 expression and its prognostic significance in breast cancer patients. Tumour Biol. 2015. doi:10.1007/s13277-015-4465-0.CrossRef

44.

Liu H, Lv Z, Guo E. Knockdown of long noncoding RNA SPRY4-IT1 suppresses glioma cell proliferation, metastasis and epithelial-mesenchymal transition. Int J Clin Exp Pathol. 2015;8(8):9140–6.

45.

Lv W, Wang L, Lu J, Mu J, Liu Y, Dong P. Long noncoding RNA KIAA0125 potentiates cell migration and invasion in gallbladder cancer. BioMed Res Int. 2015;2015:108458. doi:10.1155/2015/108458.CrossRef

46.

Xu S, Sui S, Zhang J, Bai N, Shi Q, Zhang G, et al. Downregulation of long noncoding RNA MALAT1 induces epithelial-to-mesenchymal transition via the PI3K-AKT pathway in breast cancer. Int J Clin Exp Pathol. 2015;8(5):4881–91.

47.

Wang TH, Lin YS, Chen Y, Yeh CT, Huang YL, Hsieh TH, et al. Long non-coding RNA AOC4P suppresses hepatocellular carcinoma metastasis by enhancing vimentin degradation and inhibiting epithelial-mesenchymal transition. Oncotarget. 2015;6(27):23342–57. doi:10.18632/oncotarget.4344.CrossRef

48.

Han Y, Ye J, Wu D, Wu P, Chen Z, Chen J, et al. LEIGC long non-coding RNA acts as a tumor suppressor in gastric carcinoma by inhibiting the epithelial-to-mesenchymal transition. BMC Cancer. 2014;14:932. doi:10.1186/1471-2407-14-932.CrossRef

49.

Xue M, Pang H, Li X, Li H, Pan J, Chen W. Long noncoding RNA UCA1 promotes bladder cancer cell migration and invasion via hsa-miR-145/ ZEB1/2 /FSCN1 pathway. Cancer Sci. 2015. doi:10.1111/cas.12844.CrossRef

50.

Yue B, Qiu S, Zhao S, Liu C, Zhang D, Yu F, et al. LncRNA-ATB mediated E-cadherin repression promotes the progression of colon cancer and predicts poor prognosis. J Gastroenterol Hepatol. 2015. doi:10.1111/jgh.13206.CrossRef

51.

Bischof O, Martinez-Zamudio RI. MicroRNAs and lncRNAs in senescence: a re-view. IUBMB Life. 2015;67(4):255–67. doi:10.1002/iub.1373.CrossRef

Title: RETRACTED ARTICLE: Long non-coding RNA TUSC7 acts a molecular sponge for miR-10a and suppresses EMT in hepatocellular carcinoma
Authors: Yufeng Wang
Zhikui Liu
Bowen Yao
Changwei Dou
Meng Xu
Yumo Xue
Linglong Ding
Yuli Jia
Hongyong Zhang
Qing Li
Kangsheng Tu
Yang Jiao
Qingguang Liu
Cheng Guo
Publication date: 01-08-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 8/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-4892-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2016

Pyruvate dehydrogenase B promoted the growth and migration of the nasopharyngeal carcinoma cells

RETRACTED ARTICLE: Evaluation of mRNA expression levels of IL-17A and IL-10 cytokines in cervical cancer

Toll-like receptor 5 and 7 expression in adenoid cystic carcinoma of major salivary glands

Three novel mutations of APC gene in Chinese patients with familial adenomatous polyposis

CLPTM1L polymorphism as a protective factor for lung cancer: a case–control study in southern Chinese population

MGMT in colorectal cancer: a promising component of personalized treatment

Keynote webinar | Spotlight on antibody–drug conjugates in cancer